FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803886706> ?p ?o ?g. }

• W2803886706 endingPage "724" @default.
• W2803886706 startingPage "715" @default.
• W2803886706 abstract "Bone loss is one of the important extra-intestinal manifestations in patients with inflammatory bowel diseases (IBDs). Compounds derived from natural products have been used to treat IBDs. However, the role of natural products on IBD-induced bone loss is not completely clarified. In the present study, we observed the effects of dihydroartemisinin (DHA), an antimalaria drug, on IBD and IBD-induced bone loss in a rat model. Chronic IBD model was established in Sprague-Dawley rats by giving them 2.5% dextran sodium sulfate in drinking water. DHA was given by intraperitoneal injection. Blood, colon, and bone samples were collected for biomarker assay and histological analysis. There was an obvious increase in tumor necrotic factor (TNF) α and receptor activator of nuclear factor (NF)-kB ligand (RANKL), and decrease in procollagen type 1 N-terminal propeptide (P1NP) level in IBD groups compared with the normal control (p < 0.05). The disease activity score of IBD rats was significantly higher than the control (p < 0.01). Obvious decrease in disease activity score, TNFα, and RANKL level and increase in P1NP were observed in DHA-treated IBD rats. Bone loss, shown as the decrease in bone mineral density, bone volume fraction, and trabecular number and increase in trabecular separation were observed in IBD rats compared with control (p < 0.01). DHA treatment obviously abolished the bone loss, in particular in the high-dose group (p < 0.05). DHA treatment also inhibited the excessive osteoclast formation; RANKL protein expression; and RANK, TRAF6, Fra-1, NFATc1 mRNA expression induced by IBD. Our data indicated that DHA may be a potential therapeutic agent for IBD and IBD-induced bone loss. Impact statement Bone loss is one of the important extra-intestinal manifestations in patients with inflammatory bowel diseases (IBDs). Studies have shown that compounds derived from natural products are useful in the treatment of IBDs. However, few studies have investigated the role of compounds derived from natural products in treatment of osteoporosis in IBDs. The current study aimed to show the effects of dihydroartemisinin (DHA), antimalaria drug, on bone loss in a rat model of IBD. The findings showed that DHA intervention dose dependently protected against bone loss in IBD rats by inhibiting tumor necrotic factor α production and osteoclast formation. These findings highlights that DHA may be beneficial for bone health in those patients with IBD." @default.
• W2803886706 created "2018-06-01" @default.
• W2803886706 creator A5013447364 @default.
• W2803886706 creator A5014142094 @default.
• W2803886706 creator A5029482984 @default.
• W2803886706 creator A5042536439 @default.
• W2803886706 creator A5070650183 @default.
• W2803886706 creator A5085347973 @default.
• W2803886706 date "2018-05-01" @default.
• W2803886706 modified "2023-09-27" @default.
• W2803886706 title "The effects of dihydroartemisinin on inflammatory bowel disease-related bone loss in a rat model" @default.
• W2803886706 cites W1967949491 @default.
• W2803886706 cites W1971855336 @default.
• W2803886706 cites W1987767675 @default.
• W2803886706 cites W1998367468 @default.
• W2803886706 cites W2007930847 @default.
• W2803886706 cites W2007945453 @default.
• W2803886706 cites W2008290036 @default.
• W2803886706 cites W2016827484 @default.
• W2803886706 cites W2019559265 @default.
• W2803886706 cites W2024050143 @default.
• W2803886706 cites W2027651381 @default.
• W2803886706 cites W2037464255 @default.
• W2803886706 cites W2039057018 @default.
• W2803886706 cites W2041738324 @default.
• W2803886706 cites W2048299560 @default.
• W2803886706 cites W2053303708 @default.
• W2803886706 cites W2068885672 @default.
• W2803886706 cites W2074031000 @default.
• W2803886706 cites W2076448740 @default.
• W2803886706 cites W2093252878 @default.
• W2803886706 cites W2095139297 @default.
• W2803886706 cites W2095164057 @default.
• W2803886706 cites W2099451618 @default.
• W2803886706 cites W2102523286 @default.
• W2803886706 cites W2107032681 @default.
• W2803886706 cites W2113741061 @default.
• W2803886706 cites W2118567646 @default.
• W2803886706 cites W2120796946 @default.
• W2803886706 cites W2144081914 @default.
• W2803886706 cites W2146906769 @default.
• W2803886706 cites W2149402161 @default.
• W2803886706 cites W2151088711 @default.
• W2803886706 cites W2158727573 @default.
• W2803886706 cites W2215407483 @default.
• W2803886706 cites W2244913399 @default.
• W2803886706 cites W2321061041 @default.
• W2803886706 cites W2349910005 @default.
• W2803886706 cites W2531215325 @default.
• W2803886706 cites W2532816214 @default.
• W2803886706 cites W2558579523 @default.
• W2803886706 cites W2734990106 @default.
• W2803886706 cites W2738422158 @default.
• W2803886706 cites W2755726563 @default.
• W2803886706 cites W2774020342 @default.
• W2803886706 doi "https://doi.org/10.1177/1535370218769420" @default.
• W2803886706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6378506" @default.
• W2803886706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29763384" @default.
• W2803886706 hasPublicationYear "2018" @default.
• W2803886706 type Work @default.
• W2803886706 sameAs 2803886706 @default.
• W2803886706 citedByCount "15" @default.
• W2803886706 countsByYear W28038867062018 @default.
• W2803886706 countsByYear W28038867062019 @default.
• W2803886706 countsByYear W28038867062020 @default.
• W2803886706 countsByYear W28038867062021 @default.
• W2803886706 countsByYear W28038867062022 @default.
• W2803886706 countsByYear W28038867062023 @default.
• W2803886706 crossrefType "journal-article" @default.
• W2803886706 hasAuthorship W2803886706A5013447364 @default.
• W2803886706 hasAuthorship W2803886706A5014142094 @default.
• W2803886706 hasAuthorship W2803886706A5029482984 @default.
• W2803886706 hasAuthorship W2803886706A5042536439 @default.
• W2803886706 hasAuthorship W2803886706A5070650183 @default.
• W2803886706 hasAuthorship W2803886706A5085347973 @default.
• W2803886706 hasBestOaLocation W28038867062 @default.
• W2803886706 hasConcept C126322002 @default.
• W2803886706 hasConcept C134018914 @default.
• W2803886706 hasConcept C170033053 @default.
• W2803886706 hasConcept C170493617 @default.
• W2803886706 hasConcept C17991360 @default.
• W2803886706 hasConcept C203014093 @default.
• W2803886706 hasConcept C2776033226 @default.
• W2803886706 hasConcept C2776120307 @default.
• W2803886706 hasConcept C2776541429 @default.
• W2803886706 hasConcept C2776886416 @default.
• W2803886706 hasConcept C2778048844 @default.
• W2803886706 hasConcept C2778260677 @default.
• W2803886706 hasConcept C2778371730 @default.
• W2803886706 hasConcept C2779134260 @default.
• W2803886706 hasConcept C2779428903 @default.
• W2803886706 hasConcept C2780426850 @default.
• W2803886706 hasConcept C2781160685 @default.
• W2803886706 hasConcept C71924100 @default.
• W2803886706 hasConcept C88045685 @default.
• W2803886706 hasConceptScore W2803886706C126322002 @default.
• W2803886706 hasConceptScore W2803886706C134018914 @default.
• W2803886706 hasConceptScore W2803886706C170033053 @default.

• next